| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Foreign currency exchange loss | NaN | 4* | 12.755 | 16.098 |
| Total revenue | 1,110.956 | 565.526 | 1,164.617 | 966.63 |
| Cost of research and development revenue | 340.157 | -4* | 254.753 | 148.457 |
| Cost of grant revenue | 451.683 | 396* | 769.25 | 465.134 |
| Research and development | 476.069 | 458.436 | 571.872 | 629.379 |
| General and administrative | 1,755.331 | 1,247.411 | 1,481.356 | 1,436.63 |
| Foreign currency exchange (gain) loss | 9.591 | NaN | NaN | NaN |
| Total costs and expenses | 3,013.649 | 2,101.43 | 3,089.986 | 2,695.698 |
| Loss from operations | -1,902.693 | -1,535.904 | -1,925.369 | -1,729.068 |
| Interest income | 57.191 | 83.033 | 63.467 | 49.127 |
| Interest expense-Nonrelated Party | 64.342 | 132.345 | 85.934 | 89.456 |
| Gain on sale of alphazyme | NaN | NaN | NaN | 0 |
| Interest expense-Related Party | 44.839 | -17.953 | 28.176 | 24.377 |
| Total other income (expense), net | -51.99 | -31.359 | -50.643 | -64.706 |
| Net loss | -1,954.683 | -1,567.263 | -1,976.012 | -1,793.774 |
| Basic EPS | -0.05 | -0.058* | -0.06 | -0.06 |
| Diluted EPS | -0.05 | -0.047 | -0.06 | -0.06 |
| Diluted Average Shares | 36,397,997 | 33,263,115 | 34,507,530 | 30,102,324 |
DYADIC INTERNATIONAL INC (DYAI)
DYADIC INTERNATIONAL INC (DYAI)